First Tracks Biotherapeutics, Inc.

corporate_fare Company Profile

First Tracks Biotherapeutics, Inc.

TRAX·NASDAQ·Life Sciences·CIK 0002091349

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company that develops immunology therapeutics for autoimmune and inflammatory diseases. The company operates in the United States and is based in San Diego, California. Its product pipeline includes ANB033, a novel anti-CD122 antagonist designed to target the shared beta subunit of the IL-15 and IL-2 receptors. Another key product is Rosnilimab, an antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues. Additionally, First Tracks Biotherapeutics, Inc. is developing ANB101, a BDCA2-modulating antibody specifically designed to target plasmacytoid dendritic cells (pDCs). The company was founded in 2019 and was formerly known as Biopharma Co., Inc. before changing its name to First Tracks Biotherapeutics, Inc. in February 2026.

First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) is a publicly traded company in the Life Sciences sector. Wiseek monitors TRAX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Selling Stockholders to Resell 10.5M Shares, Adding Significant Market Overhang (2026-05-15)
First Tracks Biotherapeutics Reports Q1 Results, Confirms $180M Capital Infusion Post-Spin-Off, and Advances Clinical Pipeline (2026-05-14)
First Tracks Bio Receives Positive FDA Feedback for Rosnilimab, Explores Strategic Options (2026-05-14)
Registration of 10.5M Shares for Resale by Selling Stockholders Following Spin-Off and Private Placement (2026-05-08)
First Tracks Biotherapeutics Debuts on Nasdaq with $180M Cash, Dilutive Private Placement, and New CFO (2026-04-20)

Dilution Risk

Low risk

Filing-implied dilution signals for TRAX, detected from its recent SEC filings · based on capital-structure filings through 2026-05-15.

1 recent capital raise1 shelf registration

Resale of Shares Initiated · No Proceeds to Company

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with T →

show_chartPrice Chart

Loading chart...

feed TRAX - Latest Insights

Filing Type

Date Range

TRAX

May 15, 2026, 4:06 PM EDT

Filing Type: 424B3

Importance Score:

Selling Stockholders to Resell 10.5M Shares, Adding Significant Market Overhang

Price at Filing: $14.00

Real-time Price: $41.21

Change: +$27.21 (+194%)

Market Cap: $1.438B

Sentiment: Negative

View Wiseek Article

TRAX

May 14, 2026, 4:32 PM EDT

Filing Type: 10-Q

Importance Score:

First Tracks Biotherapeutics Reports Q1 Results, Confirms $180M Capital Infusion Post-Spin-Off, and Advances Clinical Pipeline

Price at Filing: $18.16

Real-time Price: $41.21

Change: +$23.05 (+127%)

Market Cap: $1.438B

Sentiment: Positive

View Wiseek Article

TRAX

May 14, 2026, 4:15 PM EDT

Source: GlobeNewswire

Importance Score:

First Tracks Bio Receives Positive FDA Feedback for Rosnilimab, Explores Strategic Options

Price at Filing: $18.16

Real-time Price: $41.21

Change: +$23.05 (+127%)

Market Cap: $1.438B

Sentiment: Positive

View Wiseek Article

TRAX

May 08, 2026, 4:37 PM EDT

Filing Type: S-1

Importance Score:

Registration of 10.5M Shares for Resale by Selling Stockholders Following Spin-Off and Private Placement

Price at Filing: $16.97

Real-time Price: $41.21

Change: +$24.24 (+143%)

Market Cap: $1.438B

Sentiment: Negative

View Wiseek Article

TRAX

Apr 20, 2026, 5:23 PM EDT

Filing Type: 8-K

Importance Score:

First Tracks Biotherapeutics Debuts on Nasdaq with $180M Cash, Dilutive Private Placement, and New CFO

Price at Filing: $19.59

Real-time Price: $41.21

Change: +$21.62 (+110%)

Market Cap: $1.438B

Sentiment: Neutral

View Wiseek Article

corporate_fare Company Profile